IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 延遲寄發通函 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 茲 提 述 本 公 司 日 期 為 二 零 二 五 年 八 月 十 五 日 之 公 告（「該公告」），內 容 有 關 於 公開市場交易中潛在購買總值高達30億 港 元 之 加 密 貨 幣（「潛在加密貨幣購買」） 之 重 大 收 購 事 項。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。 誠 如 該 公 告 所 披 露，載 有（其 中 包 括）購 買 授 權 及 潛 在 加 密 貨 幣 購 買 之 進 一 步 詳 情、股 東 特 別 大 會 通 告 及 上 市 規 則 規 定 之 其 他 資 料 之 通 函，預 期 將 於 二 零 二 ...

Core Viewpoint - The emergence of "on-chain healthcare" in the Hong Kong stock market is marked by significant investments in digital asset models, particularly through the tokenization of real-world assets (RWA) in the healthcare sector [1][5]. Group 1: Company Actions - Huajian Medical announced a plan to invest HKD 31.42 billion to acquire a 20.31% stake in Guofu Quantum, a financial technology platform, indicating a shift towards digital asset integration in healthcare [1][2]. - The company initiated a digital transformation in July 2024, aiming to tokenize ownership of 3,000 IVD testing devices and further develop an RWA exchange strategy [2]. - Other companies like Meinian Health and Hanyu Pharmaceutical are also exploring RWA models, with Hanyu's stock surging by 19.98% after announcing the tokenization of future revenue rights for its GLP-1 weight loss drug pipeline [3][5]. Group 2: Industry Trends - The RWA concept, which began in 2017, aims to enhance liquidity in traditional financial assets by digitizing them on the blockchain, with applications expanding to various asset classes [4]. - The healthcare industry faces common challenges such as financing difficulties due to long development cycles and high costs, making RWA tokenization an attractive solution to lower investment barriers and attract global capital [5][6]. Group 3: Market Reactions and Challenges - The rapid announcements from multiple healthcare companies have led to a fervent response in the capital markets, with significant stock price increases observed [3][5]. - However, there are concerns regarding the potential for speculative behavior, as some companies may be leveraging the trend without genuine innovation [6]. - Key challenges include regulatory compliance across different jurisdictions, accurate asset valuation, and ensuring liquidity in RWA projects, which are critical for their success [6][7][8].

Core Viewpoint - Huajian Medical (01931) is acquiring approximately 1.848 billion shares of Guofu Quantum, representing 20.31% of its total issued share capital, for about HKD 3.142 billion, positioning Huajian Medical as the largest single shareholder of Guofu Quantum [1] Group 1 - The acquisition is a key move for Huajian Medical to advance its strategy of establishing a Real World Asset (RWA) tokenization exchange [1] - Huajian Medical possesses extensive resources in the medical industry, while its exchange offers a technology platform and trading venue for asset tokenization [1] - Guofu Quantum has strong capabilities in financial technology, providing financial licensing resources, digital asset issuance and trading capabilities, as well as expertise in quantum technology [1] Group 2 - Huajian Medical can leverage Guofu Quantum's 22.5% stake in Southern Dongying to collaboratively build a blockchain and financial technology-centric on-chain financial ecosystem [1] - This platform aims to integrate compliant digital architecture with traditional asset forms, promoting asset tokenization, fragmentation, and cross-border flow [1] - The initiative is focused on creating a new type of financial infrastructure [1]

Core Viewpoint - Huajian Medical (01931) plans to acquire approximately 1.848 billion shares of Guofu Quantum, representing 20.31% of its total issued share capital, for about HKD 3.142 billion, making Huajian the largest single shareholder of Guofu Quantum after the transaction [1] Group 1: Acquisition Details - The acquisition price for Guofu Quantum shares is approximately HKD 3.142 billion [1] - After the acquisition, Huajian Medical will hold 20.31% of Guofu Quantum's total issued share capital [1] Group 2: Strategic Importance - This acquisition is a key move for Huajian Medical to advance its strategy of establishing a Real World Asset (RWA) tokenization exchange [1] - Huajian Medical possesses extensive resources in the medical industry, while Guofu Quantum has strong capabilities in financial technology [1] Group 3: Resource Sharing and Synergy - Huajian Medical can leverage Guofu Quantum's 22.5% stake in Southern Dongying to collaboratively build a blockchain and financial technology-centric on-chain financial ecosystem [1] - The new platform aims to integrate compliant digital architecture with traditional asset forms, promoting asset tokenization, fragmentation, and cross-border flow [1]

Group 1 - Hong Kong Stock Exchange criticized Fuhong Hanlin for misusing IPO fundraising, highlighting governance and compliance issues [1] - Fuhong Hanlin's former CEO Liu Shigao was also reprimanded and required to undergo training [1] Group 2 - Xiansheng Pharmaceutical plans to raise approximately HKD 15.54 billion through a placement of 121 million shares at HKD 12.95 each, with about 90% allocated for R&D [2] - The funding will support clinical research for new drugs in China and the US, as well as expanding indications for approved innovative drugs [2] Group 3 - Huajian Medical announced the acquisition of a 20.31% stake in Guofu Quantum for approximately HKD 31.42 billion, making it the largest shareholder [3] - This acquisition is a strategic move to advance Huajian Medical's RWA (Real World Asset) tokenization initiative [3] Group 4 - Lighter Health Group submitted a prospectus for listing on the Hong Kong Stock Exchange, focusing on comprehensive health services and insurance solutions [4] - The company reported significant revenue growth from HKD 394 million in 2022 to HKD 945 million in 2024, but experienced a decline in gross margin from 82.6% to 38.3% [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 建議更新一般授權 獨立董事委員會及獨立股東之獨立財務顧問 董 事 會 建 議 更 新 現 有 一 般 授 權，以 供 董 事 配 發、發 行 及 處 理 最 多 相 當 於 股 東特別大會通過相關決議案當日本公司已發行股本20%之 新 股 份。根 據 上 市 規則第13.36(4)條，建 議 授 出 新 一 般 授 權 須 經 獨 立 股 東 於 股 東 特 別 大 會 上 以 普 通 決 議 案 批 准，方 可 作 實。 股東特別大會將舉行以考慮並酌情通過批准建議授出新一般授權之普通決 議 案。由 全 體 獨 立 非 執 行 董 事（即 仲 人 前 博 士、黃 思 樂 博 士、邰 洋 女 士、徐 達 先 生 及 ...

Group 1 - The transaction involves a share transfer of approximately HKD 31.42 billion, marking a significant shift in the ownership structure of two Hong Kong-listed companies, Guofu Quantum Innovation Co., Ltd. and Huajian Medical Holdings Limited [1][2] - Huajian Medical will acquire 20.31% of Guofu Quantum's shares, becoming its largest shareholder, while the previous major shareholder, Liu Zhiwei, will retain influence through his stake in Huajian Medical [1][3] - The acquisition is part of Huajian Medical's strategy to advance its Real World Asset (RWA) exchange initiative, integrating Guofu Quantum into its ecosystem [1][5] Group 2 - The payment method for the acquisition is through the issuance of new shares rather than cash, preserving Huajian Medical's financial strength while allowing the sellers to benefit from future value appreciation [2][3] - The share price of HKD 9.69 represents an 11.8% premium over the average closing price prior to the agreement, reflecting confidence in the company's valuation [2][3] Group 3 - Liu Zhiwei has been a pivotal figure in Hong Kong's fintech sector, transforming Guofu Quantum into a platform focused on fintech, quantum computing, and blockchain [4] - His strategic vision includes the establishment of the "Hong Kong Digital Asset Listed Companies Alliance" and a comprehensive RWA development strategy, indicating a deep understanding of the digital asset ecosystem [4][5] Group 4 - The collaboration between Huajian Medical and Guofu Quantum aims to create a closed-loop ecosystem for RWA, leveraging Guofu Quantum's financial licenses and technological expertise to enhance Huajian Medical's RWA operations [5][6] - The partnership is aligned with Hong Kong's governmental push for virtual asset development and financial technology innovation, positioning both companies to capitalize on emerging market opportunities [7][10] Group 5 - The transaction may lead to a dilution of Huajian Medical's existing shareholders' equity by approximately 16.7%, raising potential concerns among investors [9] - Effective integration of the two companies, which have differing focuses—healthcare for Huajian Medical and fintech for Guofu Quantum—will be crucial for realizing synergies [9][10] Group 6 - The RWA sector is poised for significant growth, with the potential to enhance liquidity and attract global investors through the tokenization of traditional assets [7][10] - The partnership is expected to facilitate the internationalization of Chinese assets, aligning with broader trends in global finance and digital innovation [11][12]

截至月份: 2025年8月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01931 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | USD | | 0.0005 | USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 3,000,000,000 | USD | | 0.0005 | USD | | 1,500,000 | 本月底法定/註冊股本總額： USD 1,500,000 FF301 致：香港交易 ...

Core Viewpoint - The acquisition of 20.31% stake in Guofu Quantum by Huajian Medical for approximately HKD 31.42 billion signifies a strategic move to enhance its business landscape and capitalize on the burgeoning RWA market [1][2]. Group 1: Strategic Considerations - The acquisition is driven by Huajian Medical's development needs and the trends in the RWA industry, which is projected to reach a market size of USD 16 trillion by 2030, accounting for 10% of global GDP [2]. - Huajian Medical aims to create a new growth curve through the establishment of the world's first innovative drug intellectual property RWA exchange, ivd.xyz, utilizing a "NewCo + RWA + stablecoin" model to tokenize high-value medical assets [2][3]. - The RWA technology allows for the segmentation of early-stage innovative drug pipeline assets into smaller tokens, broadening financing channels and improving efficiency [2]. Group 2: Market Opportunities - In the first half of 2025, China's innovative drug License-out total reached approximately USD 66 billion, surpassing the total BD transaction amount for 2024, indicating a significant opportunity for Huajian Medical's RWA business [3]. - Guofu Quantum, with its comprehensive financial licenses and expertise in quantum computing, AI, and blockchain, complements Huajian Medical's RWA strategy, addressing challenges such as the scarcity of financial licenses and expertise in digital assets [3][4]. Group 3: Business Synergy - The collaboration between Huajian Medical and Guofu Quantum is expected to create a complete ecosystem for the tokenization of innovative drug intellectual property, leveraging Huajian's medical industry resources and Guofu's financial technology capabilities [4]. - Huajian Medical can utilize Guofu Quantum's 22.5% stake in Southern Dongying to build a blockchain and financial technology-centric on-chain financial ecosystem, promoting asset tokenization and cross-border flow [4]. Group 4: Future Growth Potential - Post-acquisition, Huajian Medical is poised to expand its RWA asset types and enhance its market competitiveness by leveraging Guofu Quantum's resources [5][6]. - The partnership is expected to attract more enterprises into the RWA ecosystem, facilitating the tokenization of assets beyond innovative drugs and enhancing Huajian Medical's role as a bridge between Chinese assets and global capital [6][7]. - With the growing RWA market, Huajian Medical's unique position in the medical asset tokenization space, combined with its upgraded financial licenses and technical capabilities, positions it favorably for future competition [7]. Group 5: Conclusion - The acquisition represents a significant resource integration effort, aiming to reconstruct the link between finance and industry through RWA, with Huajian Medical potentially becoming a model for the digitalization of quality Chinese assets and compliant global capital allocation [8]. - The deepening synergy between the two companies may drive a new paradigm in the RWA industry, transitioning from single asset tokenization to a comprehensive ecosystem value co-creation [8].

Core Viewpoint - A strategic acquisition valued at HKD 3.142 billion is reshaping China's global competitive landscape in the Real World Asset (RWA) tokenization sector [1] Group 1: Strategic Collaboration - The acquisition involves Huajian Medical acquiring approximately 1.848 billion shares of Guofu Quantum, representing 20.31% of the latter's issued share capital, for a total consideration of HKD 3.142 billion [1][4] - This transaction positions Huajian Medical as the largest shareholder of Guofu Quantum, which holds multiple financial licenses in Hong Kong, thereby creating a crucial bridge between traditional finance and Web3 on-chain finance [4][5] - The collaboration is expected to release significant synergies, combining Huajian Medical's leadership in medical testing equipment distribution with Guofu Quantum's comprehensive technology and financial investment platform [5] Group 2: Policy Alignment - The strategic move aligns with national policy directions aimed at fostering technological financial innovation, as outlined in a joint policy document by several Chinese government departments [6][7] - Recent regulatory advancements in Hong Kong, including the implementation of a stablecoin licensing regime, provide a clear compliance framework for RWA token issuance and trading [7] Group 3: Economic Impact - The acquisition's strategic value extends beyond commercial interests, aiming to enhance national innovation and public welfare by improving the liquidity of high-value medical assets through RWA tokenization [8] - The Chinese innovative drug transaction volume is projected to reach USD 60.8 billion in the first half of 2025, reflecting a 129% year-on-year increase, indicating growing global recognition of Chinese innovative drug assets [8] Group 4: Ecosystem Development - Huajian Medical is accelerating the establishment of an RWA exchange platform and on-chain financial ecosystem, including applying for a stablecoin license in the U.S. [9] - The company has initiated a strategic partnership with HashKey to enhance its Ethereum (ETH) treasury strategy, aiming to become a leading entity in ETH reserves within the Hong Kong and global markets [9] - The formation of the "Hong Kong Digital Asset Listed Companies Association" will support Huajian Medical's ecosystem expansion, connecting various stakeholders in the digital asset space [9] Group 5: Industry Growth - The RWA sector is transitioning from concept validation to large-scale application, with total locked value (TVL) in RWA reaching USD 12.5 billion by June 2025, a 124% increase from 2024 [9] - The market size surged from USD 8.6 billion to USD 23 billion in the first half of 2025, marking an increase of over 260% [9] Group 6: Strategic Significance - The partnership between Huajian Medical and Guofu Quantum signifies a critical step for China in the RWA infrastructure sector, potentially securing a first-mover advantage in global competition and enhancing the country's autonomous capabilities in digital financial infrastructure [10]